Monte Rosa Therapeutics, Inc. GLUE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $159.86M+23.1% | $129.88M-37.7% | $208.34M+200% | $69.43M-11.6% | $78.53M-65.0% | ||
| $4.95M-0.1% | $4.95M+0.1% | $4.95M0.0% | $4.95M+1.4% | $4.88M+0.3% | ||
| $23.29M+9.0% | $21.37M-2.9% | $22.01M-11.4% | $24.84M+2.7% | $24.19M-3.0% | ||
| $677.55M+72.3% | $393.19M-2.1% | $401.82M+34.2% | $299.47M-9.9% | $332.28M-12.0% | ||
| $28.41M+9.3% | $25.99M-5.8% | $27.6M-5.0% | $29.05M-1.0% | $29.34M-0.5% | ||
| $24.69M+1.3% | $24.39M-2.7% | $25.07M-2.4% | $25.67M-2.2% | $26.26M-2.1% | ||
| $832K+462% | $148K-64.0% | $411K-7.6% | $445K+1.1% | $440K+283% | ||
| $736.43M+64.1% | $448.66M-2.4% | $459.84M+27.9% | $359.59M-8.5% | $393.2M-10.4% | ||
| $7.9M+123% | $3.55M-75.5% | $14.51M+160% | $5.58M-14.0% | $6.49M-62.3% | ||
| $103.64M-6.9% | $111.33M-0.5% | $111.89M+1,288% | $8.06M-52.2% | $16.86M+4.4% | ||
| $4.48M+2.0% | $4.4M+3.7% | $4.24M+3.6% | $4.09M+5.9% | $3.87M+4.1% | ||
| $71.04M+10.6% | $64.21M+4.5% | $61.44M+46.8% | $41.85M-29.3% | $59.22M-62.3% | ||
| $34.58M-0.6% | $34.79M-3.2% | $35.93M-3.0% | $37.04M-2.5% | $38M-2.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $214.51M-0.5% | $215.6M+0.7% | $214M+134% | $91.51M-22.5% | $118.04M-45.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $8K+14.3% | $7K+16.7% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $1.05B+46.8% | $714.09M+5.0% | $680.16M+0.7% | $675.45M+0.8% | $670.19M+0.8% | ||
| -$521.72M-9.3% | -$477.21M-10.7% | -$431.08M-6.7% | -$404M-3.1% | -$391.7M+10.7% | ||
| -$4.75M-24.0% | -$3.83M-17.9% | -$3.25M+3.7% | -$3.37M-1.3% | -$3.33M+0.8% | ||
| $521.92M+124% | $233.06M-5.2% | $245.84M-8.3% | $268.08M-2.6% | $275.16M+23.4% | ||
| $736.43M+64.1% | $448.66M-2.4% | $459.84M+27.9% | $359.59M-8.5% | $393.2M-10.4% | ||
| —— | —— | —— | —— | —— | ||
| $4.61M+0.2% | $4.6M-7.4% | $4.97M+109% | $2.37M+68.3% | $1.41M+714% | ||
| $832K+462% | $148K-64.0% | $411K-7.6% | $445K+1.1% | $440K+283% | ||
| $24.69M+1.3% | $24.39M-2.7% | $25.07M-2.4% | $25.67M-2.2% | $26.26M-2.1% | ||
| $24.69M+1.3% | $24.39M-2.7% | $25.07M-2.4% | $25.67M-2.2% | $26.26M-2.1% | ||
| $832K+462% | $148K-64.0% | $411K-7.6% | $445K+1.1% | $440K+283% | ||
| $24.69M+1.3% | $24.39M-2.7% | $25.07M-2.4% | $25.67M-2.2% | $26.26M-2.1% | ||
| $832K+462% | $148K-64.0% | $411K-7.6% | $445K+1.1% | $440K+283% | ||
| $25.59M-4.1% | $26.69M+49.1% | $17.9M+30.0% | $13.77M-15.5% | $16.29M-13.3% | ||
| $33.06M+11.8% | $29.57M+19.3% | $24.79M+34.7% | $18.41M-43.5% | $32.58M-72.2% | ||
| $5.26M-0.1% | $5.27M+11.1% | $4.74M+4.0% | $4.56M+15.1% | $3.96M+7.0% | ||
| $39.06M-0.3% | $39.19M-2.4% | $40.17M-2.3% | $41.13M-1.8% | $41.86M-2.0% | ||
| $1.05B+46.8% | $714.09M+5.0% | $680.16M+0.7% | $675.45M+0.8% | $670.19M+0.8% | ||
| $8K+14.3% | $7K+16.7% | $6K0.0% | $6K0.0% | $6K0.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $5.26M-0.1% | $5.27M+11.1% | $4.74M+4.0% | $4.56M+15.1% | $3.96M+7.0% | ||
| $4.61M+0.2% | $4.6M-7.4% | $4.97M+109% | $2.37M+68.3% | $1.41M+714% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Monte Rosa Therapeutics, Inc.'s total assets?
- Monte Rosa Therapeutics, Inc. (GLUE) holds $736.4M in total assets, up 87.3% year over year.
- How much debt does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. carries $39.1M in total debt against $521.9M of shareholders' equity, a debt-to-equity ratio of 0.07.
- How much cash does Monte Rosa Therapeutics, Inc. have?
- Monte Rosa Therapeutics, Inc. holds $159.9M in cash and equivalents.
- Can Monte Rosa Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 9.54 — current assets exceed current liabilities.
- Where does Monte Rosa Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
